ֱ

FDA OKs Vraylar for Depression; Schizophrenia Fingerprint? Fanapt Works in Bipolar

— News and commentary from the psychiatry world

MedpageToday
Illustration of a brain shaped maze.

The FDA has approved as an adjunctive treatment for major depressive disorder, the company announced.

allegedly dispensed thousands of unlawful prescriptions for attention deficit-hyperactivity disorder (ADHD) stimulants like dextroamphetamine/amphetamine (Adderall), according to the Drug Enforcement Administration.

46%: that's the proportion of U.S. teens who said they've , according to a Pew Research Center survey.

The did not significantly increase the risk for serotonin syndrome in people on antidepressants, a cohort study of older adults found. (JAMA Network Open)

A smartphone-based self-management intervention wasn't much help for in people with bipolar disorder, though a hint of benefit was seen in low-risk patients. (JAMA Psychiatry)

Can a ? (Schizophrenia Bulletin)

Iloperidone tablets (Fanapt) significantly improved core symptoms of mania in adults with acute manic and mixed episodes associated with bipolar I disorder, according to . The drug is already FDA approved for adults with schizophrenia.

More women than men said they in the past 2 years (50% vs 35%), but only half of them obtained an appointment for care, the 2022 Kaiser Family Foundation Women's Health Survey showed.

Cerevel Therapeutics' -- a positive allosteric modulator designed to selectively target the M4 muscarinic receptor subtype -- was cleared of blood pressure risks in people with schizophrenia during an 8-week study designed in line with FDA guidance.

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.